Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Health Information and Libraries Journal|August 2, 2014
Reporting methodological search filter performance comparisons: a literature reviewJennifer Harbour, Cynthia Fraser, Carol Lefebvre, et al.
Pharmacoeconomics - Open|March 25, 2020
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAngela Stainthorpe, Nigel Fleeman, Rachel Houten, et al.
Pharmacoeconomics|October 12, 2013
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisalSophie Beale, Rumona Dickson, Adrian Bagust, et al.
Health Technology Assessment (Winchester, England)|December 1, 2017
Assessing the performance of methodological search filters to improve the efficiency of evidence information retrieval: five literature reviews and a qualitative studyCarol Lefebvre, Julie Glanville, Sophie Beale, et al.
Pharmacoeconomics|April 24, 2015
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group PerspectiveNigel Fleeman, Adrian Bagust, Sophie Beale, et al.
Pharmacoeconomics - Open|September 21, 2023
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, et al.
Pharmacoeconomics|March 31, 2018
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAngela Stainthorpe, Janette Greenhalgh, Adrian Bagust, et al.
Pharmacoeconomics|November 28, 2017
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology AppraisalNigel Fleeman, Ahmed Abdulla, Adrian Bagust, et al.
Pharmacoeconomics|September 13, 2014
Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Health Technology Assessment (Winchester, England)|April 22, 2015
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysisJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.
Pageof 4